3 Australian Growth Stocks With Healthy Balance Sheets And Strong Earnings Forecasts

Global bond yields are moving as investors react to shifting expectations for central bank policy. That creates pockets of volatility in many assets, yet it also shines a spotlight on companies where analysts still see solid earnings growth and balance sheets that can handle bumps in the road. This article highlights three stocks from the Healthy high growth potential screener that fit that profile and explains what makes each one worth a closer look.

The three stocks below are just a starting sample, since the full Healthy high growth potential screen surfaced 93 more companies with similarly compelling earnings and balance sheet profiles that are not covered in this article. If you want to quickly identify and analyze the ideas that fit your own risk and return preferences, head straight into the Healthy high growth potential screener.

Mesoblast (ASX:MSB)

Overview: Mesoblast is a Melbourne based biotech that develops regenerative medicines built on mesenchymal lineage cells, with late stage Remestemcel L programs targeting severe inflammatory diseases such as steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as chronic heart failure and chronic low back pain. These advanced cell therapy programs are the main reason analysts link Mesoblast to the Healthy high growth potential theme, because successful approvals could shift it from a clinical stage developer to a commercial earnings story.

Operations: Mesoblast currently generates its revenue primarily from the development of its cell technology platform for commercialization, reporting about $65 million from this segment.

Market Cap: A$3.1b

Mesoblast gives you exposure to late stage cell therapies where clinical and commercial progress can translate quickly into earnings growth if trials and regulatory reviews go to plan. Analysts expect strong gains in both revenue and profitability over the next few years, yet the company is still clinical heavy and reported a loss today, so execution on Phase III trials and label expansions will matter a lot. Recent milestones, including full enrollment in the Phase III chronic low back pain study and rising Ryoncil product revenues, show that the pipeline is moving, but heavy reliance on external borrowing and a premium valuation versus many biotechs keep the risk side of the ledger real.

Mesoblast’s late stage pipeline could be closer to a revenue inflection than many investors realise, yet its borrowing and current losses raise sharp questions about durability. Get the context in the analyst forecasts for Mesoblast

Build your own high growth shortlist

Mesoblast and the two other stocks in this article all surfaced from a single Simply Wall St screener, and you can run the same kind of search tailored to your own rules. Use our flexible Screener to mix filters like future growth, valuation and balance sheet strength, or jump straight into our curated Investing Ideas for ready made shortlists based on common investing themes.

Westgold Resources (ASX:WGX)

Overview: Westgold Resources is a Perth based gold producer focused on exploring, developing and operating gold mines across its Murchison and Southern Goldfields hubs in Western Australia. Its connection to the Healthy high growth potential theme comes from these large scale gold mining operations, where analysts link higher output and cash flow from existing mines and new underground projects to strong earnings growth expectations supported by a balance sheet considered acceptable for that expansion.

Operations: Westgold Resources generates its revenue from gold mining in Western Australia, with about A$1.3b from Murchison and A$691 million from Southern Goldfields, all within Australia.

Market Cap: A$5.4b

Westgold Resources may be of interest to investors seeking direct exposure to growing gold production in Western Australia, supported by assets such as Murchison and Southern Goldfields, which analysts link to roughly 40.11% annual earnings growth forecasts. Recent projects such as the Cue Hub Expansion Plan and the enlarged Fletcher Ore Reserve at Beta Hunt are associated with higher throughput and potential cash flow gains. These initiatives are reported to be backed by liquidity of around A$939 million and an undrawn A$600 million facility to fund expansion. The company is also described as having high quality earnings with improving margins and a stronger return on equity outlook, although reliance on external borrowing and exposure to gold prices and a single region keep risk firmly on the radar.

Westgold Resources has an accelerating growth story tied to its Murchison and Southern Goldfields hubs. The real question, however, is how that growth lines up with funding and risk. Get the full picture in the analyst forecasts for Westgold Resources

Lynas Rare Earths (ASX:LYC)

Overview: Lynas Rare Earths is a Perth based miner and processor of rare earth minerals, with its Mt Weld mine in Western Australia and processing plants in Kalgoorlie and Malaysia supplying key elements like neodymium and praseodymium used in permanent magnets for electric vehicles and wind turbines. This integrated rare earths chain is the clearest link to the Healthy high growth potential theme, since analysts connect earnings growth expectations to demand from clean energy and EV markets rather than to Lynas’s smaller corporate services activity.

Operations: Lynas generates about A$716 million in revenue from its Rare Earth Operations segment.

Market Cap: A$16.4b

Lynas Rare Earths provides focused exposure to rare earths that feed the EV and wind turbine supply chain. Analysts in the market currently forecast revenue growth of about 24% a year and earnings growth of around 43% a year over the next 3 years, alongside assumptions of wider profit margins. The stock’s appeal in a Healthy high growth potential screen comes from this combination of growth expectations and an integrated asset base that runs from Mt Weld ore through to advanced materials output. Risks include sensitivity to rare earth pricing, the impact of regulatory decisions in Malaysia, and reliance on debt funding, all of which could affect how much of the forecast growth appears in future earnings.

Lynas Rare Earths is often treated as a simple EV and wind power proxy, yet the real story is in how growth expectations stack up against project and policy risk. Get the full context in the analyst forecasts for Lynas Rare Earths

Seeking Fresh Alternatives Before They Fly

Fresh ideas often move first, and the best entry points rarely stay open for long. Look for potential breakout momentum while it matters and before the crowd reacts.

• Scan for resilient income streams and keep your cash flow working harder with a curated pool of 6 dividend fortresses that focus on stability alongside yield.
• Review a hand picked group of 9 top copper producer stocks related to long term metal demand and production scale in the context of global electrification trends.
• Explore potential opportunities in precious metals producers by concentrating on a refined set of 9 top silver producer stocks instead of sorting through the entire sector yourself.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com